TY  - BOOK
AU  - Hackmann,Meredith
AU  - National Academies of Sciences,Engineering,and Medicine (U.S.).
AU  - Wizemann,Theresa M.
AU  - Beachy,Sarah H.
ED  - Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products (Workshop)
TI  - Exploring sources of variability related to the clinical translation of regenerative engineering products: proceedings of a workshop 
T2  - A consensus study report of the National Academies of Sciences, Engineering, Medicine
SN  - 9780309489096
AV  - QH499 .E975 2019
PY  - 2019///
CY  - Washington, DC
PB  - National Academies Press
KW  - Regenerative medicine
KW  - Congresses
KW  - Standards
KW  - Quality control
KW  - Tissue engineering
KW  - Tissue Engineering
KW  - standards
KW  - Regenerative Medicine
KW  - Quality Control
KW  - Translational Research, Biomedical
KW  - Electronic Books
N1  - 1; Introduction and overview --; Sources of variability associated with regenerative therapies : lessons from case studies --; Factors contributing to patient variability --; Addressing variability in donor tissues and cells --; Addressing variability and meeting quality expectations in the manufacturing setting --; Exploring variability and its impact on product regulation and outcomes --; Potential next steps to consider for addressing variability --; References --; Appendixes; 2; b
N2  - The emerging multidisciplinary field of regenerative engineering is devoted to the repair, regeneration, and replacement of damaged tissues or organs in the body. To accomplish this it uses a combination of principles and technologies from disciplines such as advanced materials science, developmental and stem cell biology, immunology, physics, and clinical translation. The term "regenerative engineering" reflects a new understanding of the use of tissue engineering for regeneration and also the growing number of research and product development efforts that incorporate elements from a variety of fields. Because regenerative engineered therapies rely on live cells and scaffolds, there are inherent challenges in quality control arising from variability in source and final products. Furthermore, each patient recipient, tissue donor, and product application is unique, meaning that the field faces complexities in the development of safe and effective new products and therapies which are not faced by developers of more conventional therapies. Understanding the many sources of variability can help reduce this variability and ensure consistent results. The Forum on Regenerative Medicine hosted a public workshop on October 18, 2018, in Washington, DC, to explore the various factors that must be taken into account in order to develop successful regenerative engineering products. Invited speakers and participants discussed factors and sources of variability in the development and clinical application of regenerative engineering products, characteristics of high-quality products, and how different clinical needs, models, and contexts can inform the development of a product to improve patient outcomes. This publication summarizes the presentation and discussion of the workshop
UR  - httpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2219053&site=eds-live&custid=s3260518
ER  -